doi: 10.1161/01.ATV.0000047645.37970.AB
© 2003 American Heart Association, Inc.
Editorials |
Mechanism of Action of High-Dose Factor VIIa
Points of Agreement and Disagreement
From the Center for Thrombosis and Hemostasis, University of North Carolina Chapel Hill.
Correspondence to Dr Dougald M. Monroe, University of North Carolina at Chapel Hill, Hematology/Oncology, 932 Mary Ellen Jones Bldg, CB 7035, Chapel Hill, NC 27599-7035. E-mail dmonroe@med.unc.edu
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
In an article in this issue of the Arteriosclerosis, Thrombosis, and Vascular Biology,1 Butenas and colleagues report studies looking at pharmacologic levels of factor VIIa in a model system of hemophilia. Understanding the mechanism by which high-dose factor VIIa increases thrombin generation and enhances hemostasis is important because it is currently being used very effectively in treatment of patients with hemophilia, especially those with inhibitors.2 Factor VIIa is also being tested in other clinical settings of uncontrolled bleeding.3 Previously, Mann and coworkers4 developed a model for studying coagulation that involved reassembling purified coagulation factors with phospholipid vesicles. They examined not only thrombin generation but also the precise sequence of events leading to thrombin generation. Subsequently, this group has looked at the mechanisms of coagulation using tissue factor initiation and surfaces of: phospholipid vesicles,5 isolated platelets,6 and platelets in whole blood.7 These studies provided the impetus for many of the current studies on the mechanisms of coagulation being done by Mann’s group and many other groups, including ours.8–11 This body of work has resulted in important observations that have helped define the mechanisms of the hemostatic process including demonstration of: the pivotal role of the tissue factor complex in initiating coagulation, the important role of initial thrombin generation in activating platelets, and the role of coagulation cofactor interactions.
See pages 10 and 123
In the present article by Butenas and coworkers,1 the effects of pharmacologic doses of factor VIIa on hemophilia were studied in whole blood that was supplemented with
This article has been cited by other articles:
 |
|
 |
|
  E. F. M. Wouters, K. H. Groenewegen, M. A. Dentener, and J. H. J. Vernooy Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of Exacerbations Proceedings of the ATS, December 1, 2007; 4(8): 626 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S Baxter, W. S Schroeder, Y. Cheng, and Z. P Bernstein Diminished Response to Recombinant Factor VIIa in a Patient with Idiopathic Thrombocytopenic Purpura Ann. Pharmacother., November 1, 2006; 40(11): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Brenner, R. Hoffman, D. Balashov, E. Shutluko, S. Culic, and E. Nizamoutdinova Control of Bleeding Caused by Thrombocytopenia Associated With Hematologic Malignancy: An Audit of the Clinical Use of Recombinant Activated Factor VII Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 401 - 410. [Abstract] [PDF]
|
|
|
|
 |
|
 H. R. Roberts, D. M. Monroe, and G. C. White The use of recombinant factor VIIa in the treatment of bleeding disorders Blood, December 15, 2004; 104(13): 3858 - 3864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J.H. Wielders, S. Beguin, H. C. Hemker, and T. Lindhout Factor XI-Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1138 - 1142. [Abstract] [Full Text] [PDF]
|
|